A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease
Tacrine, the first drug specifically approved for Alzheimer's disease, produces symptomatic improvement. The theoretical rationale behind treating Alzheimer's disease with tacrine is based on central cholinergic depletion. Tacrine is centrally acting, uncompetitive reversible inhibitor of acetylcholinesterase and butyrylcholinesterase. Multiple clinical trials support the effectiveness of tacrine in Alzheimer's disease. High dosages of tacrine are required for efficacy, with the potential for hepatic and mild gastrointestinal adverse effects. However, the benefits of tacrine currently outweigh its risks, and a trial of the drug should be offered to patients. As clinical experience with tacrine increases, the long term risk-benefit equation may be refined.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
1997 |
---|---|
Erschienen: |
1997 |
Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
---|---|
Enthalten in: |
Drug safety - 16(1997), 1 vom: 09. Jan., Seite 66-77 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Samuels, S C [VerfasserIn] |
---|
Themen: |
4VX7YNB537 |
---|
Anmerkungen: |
Date Completed 01.04.1997 Date Revised 16.07.2022 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM089760476 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM089760476 | ||
003 | DE-627 | ||
005 | 20231222080722.0 | ||
007 | tu | ||
008 | 231222s1997 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0300.xml |
035 | |a (DE-627)NLM089760476 | ||
035 | |a (NLM)9010644 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Samuels, S C |e verfasserin |4 aut | |
245 | 1 | 2 | |a A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease |
264 | 1 | |c 1997 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 01.04.1997 | ||
500 | |a Date Revised 16.07.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Tacrine, the first drug specifically approved for Alzheimer's disease, produces symptomatic improvement. The theoretical rationale behind treating Alzheimer's disease with tacrine is based on central cholinergic depletion. Tacrine is centrally acting, uncompetitive reversible inhibitor of acetylcholinesterase and butyrylcholinesterase. Multiple clinical trials support the effectiveness of tacrine in Alzheimer's disease. High dosages of tacrine are required for efficacy, with the potential for hepatic and mild gastrointestinal adverse effects. However, the benefits of tacrine currently outweigh its risks, and a trial of the drug should be offered to patients. As clinical experience with tacrine increases, the long term risk-benefit equation may be refined | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 7 | |a Cholinesterase Inhibitors |2 NLM | |
650 | 7 | |a Tacrine |2 NLM | |
650 | 7 | |a 4VX7YNB537 |2 NLM | |
700 | 1 | |a Davis, K L |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drug safety |d 1993 |g 16(1997), 1 vom: 09. Jan., Seite 66-77 |w (DE-627)NLM013282689 |x 1179-1942 |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:1997 |g number:1 |g day:09 |g month:01 |g pages:66-77 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 16 |j 1997 |e 1 |b 09 |c 01 |h 66-77 |